Please wait while the formulary information is being retrieved.
GALANTAMINE HBR (GALANTAMINE HBR)
- Mild to moderate alzheimer's type dementia
12 mg tablet
- 1 tablet (12 mg) by oral route 2 times per day with morning and evening meals
4 mg tablet
- 1 tablet (4 mg) by oral route 2 times per day with morning and evening meals
8 mg tablet
- 1 tablet (8 mg) by oral route 2 times per day with morning and evening meals
12 mg tablet
- 1 tablet (12 mg) by oral route 2 times per day with morning and evening meals
4 mg tablet
- 1 tablet (4 mg) by oral route 2 times per day with morning and evening meals
8 mg tablet
- 1 tablet (8 mg) by oral route 2 times per day with morning and evening meals
galantamine 12 mg tablet
- 1 tablet (12 mg) by oral route 2 times per day with morning and evening meals
galantamine 4 mg tablet
- 1 tablet (4 mg) by oral route 2 times per day with morning and evening meals
galantamine 8 mg tablet
- 1 tablet (8 mg) by oral route 2 times per day with morning and evening meals
Mild to moderate alzheimer's type dementia
- 1 tablet (4 mg) by oral route 2 times per day with morning and evening meals
- 2 tablets (8 mg) by oral route 2 times per day with morning and evening meals
- 1 tablet (8 mg) by oral route 2 times per day with morning and evening meals
- 1 tablet (12 mg) by oral route 2 times per day with morning and evening meals
- None
Contraindicated
- None
Severe
Moderate
- Anectine
- Quelicin
- succinylcholine chloride
- None
Contraindicated
- Asthma
- Atrioventricular block
- Bladder outflow obstruction
- Bradycardia
- Congenital long QT syndrome
- Disease of liver
- Duodenal ulcer
- Gastrointestinal ulcer
- Obstructive pulmonary disease
- Peptic ulcer
- Renal disease with moderate to severe impairment
- Seizure disorder
Severe
Moderate
- CYp2d6 poor metabolizer
GALANTAMINE HBR (GALANTAMINE HBR)
- Mild to moderate alzheimer's type dementia
- None
- Anorexia
- Diarrhea
- Dizziness
- Headache disorder
- Nausea
- Vomiting
- Weight loss
More Frequent
Severe
Less Severe
- Depression
- Acute abdominal pain
- Bradycardia
- Drowsy
- Dyspepsia
- Fatigue
- General weakness
- Malaise
- Syncope
- Tremor
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute generalized exanthematous pustulosis
- Atrioventricular block
- Bladder outflow obstruction
- Chest pain
- Complete atrioventricular block
- Dehydration
- Erythema multiforme
- Hepatitis
- Prolonged QT interval
- Seizure disorder
- Stevens-johnson syndrome
- Supraventricular premature beats
Less Severe
- Blurred vision
- Dysgeusia
- Flushing
- Hallucinations
- Hyperhidrosis
- Hypersomnia
- Hypertension
- Hypotension
- Lethargy
- Muscle spasm
- Muscle weakness
- Palpitations
- Paresthesia
- Skin rash
- Tinnitus
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Galantamine
No safety and efficacy established. Approved for Alzheimer's dementia.
- 1 Day – 18 Years
- No safety and efficacy established. Approved for Alzheimer's dementia.
Galantamine
- Severity Level:
B
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Galantamine
Insuff human data; low mw and plasma protein binding, excretion may occur
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff human data; low mw and plasma protein binding, excretion may occur |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Galantamine
Cardiovascular-Cholinesterase inhibitors may have vagotonic effects on the SA and AV nodes possibly resulting in bradycardia or AV block. Urogenital-May cause bladder outflow obstruction in those patients who are predisposed. Pulmonary-Use with caution in patients with pre-existing asthma or obstructive pulmonary disease. Gastrointestinal-Use with caution in patients with history of or active peptic ulcer disease or GI bleeding. Dose dependent N/V, diarrhea.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | N | Y | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- None
| Mild to moderate alzheimer's type dementia | |
| G30 | Alzheimer's disease |
| G30.0 | Alzheimer's disease with early onset |
| G30.1 | Alzheimer's disease with late onset |
| G30.8 | Other alzheimer's disease |
| G30.9 | Alzheimer's disease, unspecified |
| 0-9 | A-Z |
|---|---|
| G30 | Alzheimer's disease |
| G30.0 | Alzheimer's disease with early onset |
| G30.1 | Alzheimer's disease with late onset |
| G30.8 | Other alzheimer's disease |
| G30.9 | Alzheimer's disease, unspecified |
Formulary Reference Tool